NDC 0069-1751

Talzenna

Talazoparib

Talzenna is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is Talazoparib Tosylate.

• Product ID: 0069-1751_0a4af2c6-fb47-4122-b94c-dc24945e3be0
• NDC: 0069-1751
• Product Type: Human Prescription Drug
• Proprietary Name: Talzenna
• Generic Name: Talazoparib
• Dosage Form: Capsule
• Route of Administration: ORAL
• Marketing Start Date: 2022-01-31
• Marketing Category: NDA /
• Application Number: NDA211651
• Labeler Name: Pfizer Laboratories Div Pfizer Inc
• Substance Name: TALAZOPARIB TOSYLATE
• Active Ingredient Strength: 1 mg/1
• Pharm Classes: Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0069-1751-30

1 BOTTLE in 1 CARTON (0069-1751-30) > 30 CAPSULE in 1 BOTTLE

• Marketing Start Date: 2022-01-31
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "Talzenna" or generic name "Talazoparib"

NDC	Brand Name	Generic Name
0069-0296	Talzenna	talazoparib
0069-1195	Talzenna	talazoparib
0069-1501	Talzenna	talazoparib
0069-1751	Talzenna	talazoparib
46014-0296	Talzenna	talazoparib
46014-1195	Talzenna	talazoparib
63539-295	Talzenna	talazoparib